Back to results
US 2003/0158378 A1Published application
Chordin-Like-2 molecules and uses thereof
AssigneeAmgen, Inc., A corporation of the State of Delawar
InventorsKe Zhang, Linh Cam, Naoki Nakayama
Life of this patent
Estimating the term…
Abstract
The present invention provides Chordin-Like-2 (CHL2) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL2 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL2 polypeptides.
Claims56
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- (a) the nucleotide sequence as set forth in either SEQ ID NO:
- 1 or SEQ ID NO:
- 4;
- (b) the nucleotide sequence of the DNA insert in either ATCC Deposit Nos. PTA-1479 or PTA-1480;
- (c) a nucleotide sequence encoding the polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (d) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(c);
- and
- (e) a nucleotide sequence complementary to any of (a)-(c).
7 more elements
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide which is at least about 70 percent identical to the polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5, wherein the encoded polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in either SEQ ID NO:
- 1 or SEQ ID NO:
- 4, the nucleotide sequence of the DNA insert in either ATCC Deposit Nos. PTA-1479 or PTA-1480, or (a);
- (c) a region of the nucleotide sequence of any of SEQ ID NO:
- 1 or SEQ ID NO:
- 4, the DNA insert in either ATCC Deposit Nos. PTA-1479 or PTA-1480, (a), or (b) encoding a polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide fragment has an activity of the encoded polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5, or is antigenic;
- (d) a region of the nucleotide sequence of any of SEQ ID NO:
- 1 or SEQ ID NO:
- 4, the DNA insert in either ATCC Deposit Nos. PTA-1479 or PTA-1480, or any of (a)-(c) comprising a fragment of at least about 16 nucleotides;
- (e) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(d);
- and
- (f) a nucleotide sequence complementary to any of (a)-(d).
16 more elements
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one conservative amino acid substitution, wherein the encoded polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (b) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one amino acid insertion, wherein the encoded polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (c) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one amino acid deletion, wherein the encoded polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (d) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 which has a C- and/or N-terminal truncation, wherein the encoded polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (e) a nucleotide sequence encoding a polypeptide as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the encoded polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (f) a nucleotide sequence of any of (a)-(e) comprising a fragment of at least about 16 nucleotides;
- (g) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of any of (a)-(f);
- and
- (h) a nucleotide sequence complementary to any of (a)-(e).
26 more elements
An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- and
- (b) the amino acid sequence encoded by the DNA insert in either ATCC Deposit Nos. PTA-1479 or PTA-1480.
2 more elements
An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as set forth in either SEQ ID NO:
- 3 or SEQ ID NO:
- 6, optionally further comprising an amino-terminal methionine;
- (b) an amino acid sequence for an ortholog of any of SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (c) an amino acid sequence which is at least about 70 percent identical to the amino acid sequence of any of SEQ ID NO:
- 2 or SEQ ID NO:
- 5, wherein the polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (d) a fragment of the amino acid sequence set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 comprising at least about 25 amino acid residues, wherein the fragment has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5, or is antigenic;
- and
- (e) an amino acid sequence for an allelic variant or splice variant of the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5, the amino acid sequence encoded by the DNA insert in either ATCC Deposit Nos. PTA-1479 or PTA-1480, or any of (a)-(c).
17 more elements
An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one conservative amino acid substitution, wherein the polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (b) the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one amino acid insertion, wherein the polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (c) the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one amino acid deletion, wherein the polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (d) the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 which has a C- and/or N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- and
- (e) the amino acid sequence as set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5 with at least one modification selected from the group consisting of amino acid substitutions, amino acid insertions, amino acid deletions, C-terminal truncation, and N-terminal truncation, wherein the polypeptide has an activity of the polypeptide set forth in either SEQ ID NO:
- 2 or SEQ ID NO:
- 5.
23 more elements
A selective binding agent or fragment thereof comprising at least one complementarity determining region with specificity for a polypeptide having the amino acid sequence of any of SEQ ID NO:
- 2 or SEQ ID NO:
- 5.
A selective binding agent produced by immunizing an animal with a polypeptide comprising an amino acid sequence of any of SEQ ID NO:
- 2 or SEQ ID NO:
- 5.
An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:
- 5 with at least one conservative amino acid substitution selected from the group consisting of:
- leucine or methionine at position 2;
- methionine at position 5;
- lysine at position 6;
- alanine at position 7;
- isoleucine at position 8;
- phenylalanine at position 14;
- leucine at position 15;
- threonine at position 23;
- leucine at position 25;
- valine at position 27;
- glutamic acid at position 30;
- tyrosine at position 32;
- methionine at position 34;
- glutamine at position 36;
- lysine at position 39;
- alanine at position 41;
- threonine at position 45;
- valine at position 55;
- valine at position 59;
- asparagine at position 60;
- proline at position 66;
- asparagine at position 68;
- serine or threonine at position 72;
- valine at position 74;
- arginine at position 75;
- arginine at position 94;
- asparagine at position 99;
- serine at position 100;
- lysine at position 105;
- valine at position 106;
- tyrosine at position 113;
- serine at position 116;
- serine at position 118;
- arginine at position 120;
- leucine at position 123;
- alanine at position 125;
- alanine at position 129;
- alanine at position 139;
- threonine at position 142;
- serine at position 144;
- asparagine at position 147;
- valine at position 148;
- serine at position 149;
- alanine at position 159;
- alanine at position 160;
- alanine at position 161;
- valine at position 164;
- valine at position 166;
- valine at position 173;
- arginine at position 175;
- aspartic acid at position 177;
- alanine at position 190;
- phenylalanine at position 191;
- arginine at position 192;
- leucine at position 194;
- asparagine at position 196;
- leucine at position 205;
- alanine at position 210;
- alanine at position 212;
- serine at position 213;
- alanine at position 216;
- serine at position 217;
- alanine at position 218;
- isoleucine at position 219;
- alanine at position 222;
- leucine at position 225;
- phenylalanine at position 226;
- leucine at position 230;
- glutamine or arginine at position 233;
- glutamine at position 241;
- leucine at position 242;
- isoleucine at position 244;
- glutamine or asparagine at position 245;
- glutamine at position 249;
- leucine or valine at position 251;
- alanine at position 256;
- asparagine at position 257;
- serine at position 259;
- alanine at position 260;
- glutamine at position 261;
- phenylalanine at position 265;
- valine at position 268;
- leucine at position 269;
- leucine at position 272;
- valine at position 275;
- valine at position 278;
- glutamic acid at position 284;
- glutamic acid at position 288;
- alanine or isoleucine at position 292;
- serine at position 300;
- isoleucine at position 306;
- valine at position 313;
- serine at position 314;
- leucine at position 319;
- glutamine at position 323;
- threonine at position 324;
- alanine at position 326;
- alanine at position 327;
- serine at position 329;
- serine at position 331;
- leucine at position 334;
- asparagine at position 337;
- valine at position 339;
- leucine at position 340;
- serine at position 342;
- phenylalanine at position 344;
- glutamic acid at position 349;
- isoleucine or valine at position 354;
- methionine at position 356;
- valine at position 366;
- methionine or valine at position 368;
- isoleucine at position 371;
- leucine at position 375;
- leucine at position 376;
- glutamine at position 377;
- phenylalanine at position 381;
- asparagine at position 383;
- isoleucine at position 384;
- leucine at position 393;
- arginine at position 395;
- valine at position 398;
- alanine or valine at position 399;
- tyrosine at position 403;
- asparagine at position 406;
- isoleucine at position 409;
- alanine or valine at position 415;
- isoleucine at position 417;
- and leucine at position 421;
- wherein the polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:
- 5.
128 more elements
Dependencies are inferred from the claim text.